Company's in situ hybridization technology may lead to clinical applications

July 21, 2014

Advanced Cell Diagnostics, Inc. (ACD), developer of cell and tissue-based analysis tools and molecular diagnostic tests for personalized medicine, has announced that its RNAscope RNA in situ hybridization technology has reached two major milestones. In just three years, more than 100 peer-reviewed papers featuring the technology have been published, and with the significant increase in use of RNAscope, ACD has now built a library of more than 4,000 target probes for numerous species.

ACD representatives say that RNAscope has the sensitivity to enable researchers to detect in situ single RNA molecules and provide quantitative analysis of gene expression at a single cell level. In addition, the technology provides morphological context by showing spatial and cell-specific expression while preserving tissue architecture. RNAscope’s ability to unlock the full potential of RNA biomarkers, together with its highly reproducible and easy-to-use technology, has resulted in an average of more than six papers a month published so far in 2014. The papers range from basic research in developmental biology, neuroscience, and stem cells to clinical research such as cancer biomarkers, infectious diseases, and ophthalmology, in journals such as NatureScience,CellPLoS OnePNAS and Clinical Cancer Research.

“Publications from our customers are particularly exciting, as they show the growing validation and adoption of our technologies at the forefront of scientific research,” says Xiao-Jun Ma, ACD’s CSO. “We believe that the specific benefits of RNAscope technology will undoubtedly accelerate the translation of genomic discoveries to clinical medicine, including new therapeutics and diagnostics.” Learn more about the published research on RNAscope.

Read more